It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Malaria is a highly prevalent parasitic disease in regions with tropical and subtropical climates worldwide. Among the species of Plasmodium causing human malaria, P. vivax is the second most prevalent and the most geographically widespread species. A major target of a pre-erythrocytic vaccine is the P. vivax circumsporozoite protein (PvCSP). In previous studies, we fused two recombinant proteins representing three allelic variants of PvCSP (VK210, VK247 and P. vivax-like) to the mumps virus nucleocapsid protein to enhance immune responses against PvCSP. The objective of the present study was to evaluate the protective efficacy of these recombinants in mice challenged with transgenic P. berghei parasites expressing PvCSP allelic variants. Formulations containing Poly (I:C) or Montanide ISA720 as adjuvants elicited high and long-lasting IgG antibody titers specific to each PvCSP allelic variant. Immunized mice were challenged with two existing chimeric P. berghei parasite lines expressing PvCSP-VK210 and PvCSP-VK247. We also developed a novel chimeric line expressing the third allelic variant, PvCSP-P. vivax-like, as a new murine immunization-challenge model. Our formulations conferred partial protection (significant delay in the time to reach 1% parasitemia) against challenge with the three chimeric parasites. Our results provide insights into the development of a vaccine targeting multiple strains of P. vivax.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 University of Oxford, Nuffield Department of Medicine, The Jenner Institute, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948); University of São Paulo, Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, São Paulo, Brazil (GRID:grid.11899.38) (ISNI:0000 0004 1937 0722)
2 University of Oxford, Nuffield Department of Medicine, The Jenner Institute, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)
3 University of São Paulo, Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, São Paulo, Brazil (GRID:grid.11899.38) (ISNI:0000 0004 1937 0722)
4 Leiden University Medical Center, (LUMC, L4-Q), Department of Parasitology, Leiden Malaria Research Group, Center of Infectious Diseases, Leiden, The Netherlands (GRID:grid.10419.3d) (ISNI:0000000089452978)
5 University of Oxford, Nuffield Department of Medicine, The Jenner Institute, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948); Instituto Politécnico Nacional, IPN, Mexico City, Mexico (GRID:grid.418275.d) (ISNI:0000 0001 2165 8782)